Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D₃

Table 2

The assessment of the clinical status and immunomodulatory treatment in the subgroups of patients with deficiency, insufficiency, and normal level of 25-hydroxycholecalciferol.

Parameter	VitDd; n=56; (68%)	VitDi; n=19; (23%)	VitDn; n=7; (9%)	p
EDSS [score]	2.8 ± 0.9	2.0 ± 2.35	2.0 ± 2.3	0.005
Total number of relapses [n]	4.6 ± 2.5	4.0 ± 2.3	3.6 ± 2.3	0.42
Number of relapses per year [n]	2.66 ± 13.4	5.97 ± 23.0	0.6 ± 0.6	0.52
Hospitalizations due to MS [n]	3.44 ± 2.06	2.63 ±1.42	2.29 ±1.38	0.16
iv. GCs [n]	2.4 ± 2.1	1.8 ± 1.5	1.6 ± 1.1	0.56
Rehabilitation due to MS [%]	60.7	42.1	42.9	0.30
Treatment [%]:	-	-	-	-
(i) INF-β1a [%]	21.4	26.3	28.6	0.86
(ii) INF-β1b [%]	26.8	36.8	57.1	0.23
(iii) Copaxone [%]	8.9	5.3	0	0.65
(iv) Gilenya/Tysabri	14.2	10.5	14.3	0.92
INF- β if ever [%]	69.6	73.7	100.0	0.24

VitD₃-25-hydroxycholecalciferol, VitDd: vitamin D₃ deficiency, VitDi: vitamin D₃ insufficiency, VitDn: normal vitamin D_3, EDSS: Expanded Disability Status Scale; INF-β: interferon beta, MS: multiple sclerosis, iv. GCs: intravenous glucocorticoids.